In a report released yesterday, Nathan Rich from Goldman Sachs maintained a Hold rating on Henry Schein (HSIC – Research Report). The company’s shares closed yesterday at $69.88.
According to TipRanks, Rich is a 3-star analyst with an average return of 3.6% and a 55.24% success rate. Rich covers the Healthcare sector, focusing on stocks such as Align Tech, Sonendo, and Centene.
Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $76.17.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $89.72 and a one-year low of $60.01. Currently, Henry Schein has an average volume of 1.08M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Henry Schein (HSIC) Company Description:
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.
Read More on HSIC:
- Henry Schein receives deficiency notice from Nasdaq
- JPMorgan medical distribution analyst holds an analyst/industry conference call
- Henry Schein price target lowered to $82 from $90 at Barrington
- Henry Schein price target lowered to $78 from $84 at Piper Sandler
- Henry Schein price target lowered to $76 from $82 at Baird
